Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
RenovoRx, Inc. (RNXT)
Company Research
Source: Yahoo! Finance
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. The company's loss has recently broadened since it announced a US$8.8m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$11m, moving it further away from breakeven. As path to profitability is the topic on RenovoRx's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. According to the 4 industry analysts covering RenovoRx, the consensus is that breakeven is near. They expect the company to post a final loss in 2027, before turning a profit of US$16m in 2028. The company is therefore projected to breakev
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial OfficerGlobeNewswire
- RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific MeetingGlobeNewswire
- RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.MarketBeat
- RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific MeetingGlobeNewswire
- RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer CenterGlobeNewswire
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 2/6/26 - Form 8-K
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- RNXT's page on the SEC website